Thermo Fisher Scientific IFN beta Monoclonal Antibody (A1 (IFNb)), Functional Grade, eBioscience

Applications

Tested Dilution

Publications

Neutralization (Neu)

Assay-Dependent

-

Functional Assay (Functional)

Assay-Dependent

-

Product Specifications

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), Functional Grade, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

A1 (IFNb)

Conjugate

Functional Grade Functional Grade Functional Grade

View additional formats

• Unconjugated
• Biotin
• FITC
• Request custom conjugation

Form

Liquid

Concentration

1 mg/mL

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2866408

Product Specific Information

Description: The A1 monoclonal antibody reacts with human IFN-beta. The A1 antibody is a neutralizing antibody. IFN-beta is classified as a type I IFN which is a group of structurally and functionally related proteins demonstrating anti-viral, anti-parasitic, and anti-proliferative activities.

Applications Reported:The A1 antibody has been reported for use in cytokine neutralization.

Applications Tested: The Functional Grade Purified A1 antibody has been tested in bioassay for neutralization of IFN-beta bioactivity.

The A1 antibody at 3-6 µg/mL has been found to inhibit by 50% the biological effects of 50 pg/mL human IFN-beta (ND50), in an EMCV assay of A549 cell protection. Detailed information and protocols about cytokine bioassays and in vitro cytokine neutralization using antibodies can be found in the BestProtocols® section.

Storage and handling: Use in a sterile environment.

Filtration: 0.2 µm post-manufacturing filtered.

Purity: Greater than 90%, as determined by SDS-PAGE.

Endotoxin Level:Less than 0.001 ng/µg antibody, as determined by LAL assay.

Aggregation:Less than 10%, as determined by HPLC.

Target Information

Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response. IFNs can also inhibit the development of tumors. IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.